Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
2.62
Nov 20 • 2:34 PM ET Dollar change-0.07 Percentage change(-2.60%)
Index
-
Market Cap
14.10M
Enterprise Value
13.78M
Income
-
Sales
-
Book/sh
1.12
Cash/sh
0.13
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
12
IPO
Jan 29, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
2.34
P/C
19.86
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.32
Current Ratio
0.32
Debt/Eq
0.06
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
81.39% 60.94%
Sales past 3/5Y
- -
EPS Y/Y TTM
77.07%
Sales Y/Y TTM
-
EPS Q/Q
86.03%
Sales Q/Q
-
Insider Own
52.90%
Insider Trans
0.00%
Inst Own
1.55%
Inst Trans
-84.84%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-2.36%
SMA50
-7.58%
SMA200
-15.74%
Trades
Shs Outstand
5.38M
Shs Float
2.54M
52W High
5.12 -48.83%
52W Low
1.83 43.18%
Volatility
6.02% 11.21%
ATR (14)
0.26
RSI (14)
45.82
Beta
1.00
Rel Volume
0.20
Avg Volume
13.35K
Volume
2,205
Perf Week
0.38%
Perf Month
2.34%
Perf Quarter
-24.28%
Perf Half Y
-17.09%
Perf YTD
37.89%
Perf Year
-16.83%
Perf 3Y
-98.52%
Perf 5Y
-99.67%
Perf 10Y
-
Prev Close
2.69
Price
2.62
Change %
-2.60%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Samuel OlivierDirectorApr 27 '26Buy2.7581,818225,00081,818Apr 29 04:05 PM
Revel MichelCSO and DirectorApr 27 '26Buy2.7554,545149,999957,530Apr 29 04:05 PM
NewCelX Ltd. is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company is headquarter in Kloten, Switzerland.
CEO & Executive ChairmanMr. Ronen Twito CPA
Ph.D.Prof. Michel Revel M.D.
Chief Financial OfficerMr. Omri Hagai
Chief Business Officer & Executive DirectorMr. Alexander C. Zwyer M.B.A.
Ph.D.Dr. Eric Konofal M.D.